We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector.
- Authors
Becker, P. S.; Taylor, J. A.; Trobridge, G. D.; Zhao, X.; Beard, B. C.; Chien, S.; Adair, J.; Kohn, D. B.; Wagner, J. E.; Shimamura, A.; Kiem, H.-P.
- Abstract
One of the major hurdles for the development of gene therapy for Fanconi anemia (FA) is the increased sensitivity of FA stem cells to free radical-induced DNA damage during ex vivo culture and manipulation. To minimize this damage, we have developed a brief transduction procedure for lentivirus vector-mediated transduction of hematopoietic progenitor cells from patients with Fanconi anemia complementation group A (FANCA). The lentiviral vector FancA-sW contains the phosphoglycerate kinase promoter, the FANCA cDNA, and a synthetic, safety-modified woodchuck post transcriptional regulatory element (sW). Bone marrow mononuclear cells or purified CD34+ cells from patients with FANCA were transduced in an overnight culture on recombinant fibronectin peptide CH-296, in low (5%) oxygen, with the reducing agent, N-acetyl-L-cysteine (NAC), and a combination of growth factors, granulocyte colony-stimulating factor (G-CSF), Flt3 ligand, stem cell factor, and thrombopoietin. Transduced cells plated in methylcellulose in hypoxia with NAC showed increased colony formation compared with 21% oxygen without NAC (P<0.03), showed increased resistance to mitomycin C compared with green fluorescent protein (GFP) vector-transduced controls (P<0.007), and increased survival. Thus, combining short transduction and reducing oxidative stress may enhance the viability and engraftment of gene-corrected cells in patients with FANCA.
- Subjects
GENE therapy; FANCONI'S anemia; DNA damage; STEM cells; HYPOXEMIA
- Publication
Gene Therapy, 2010, Vol 17, Issue 10, p1244
- ISSN
0969-7128
- Publication type
Article
- DOI
10.1038/gt.2010.62